Εμφανίζονται 1 - 20 Αποτελέσματα από 79 για την αναζήτηση '"ФАКТОРЫ РИСКА СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ"', χρόνος αναζήτησης: 0,96δλ Περιορισμός αποτελεσμάτων
  1. 1
    Academic Journal

    Πηγή: Вестник интенсивной терапии, Iss 2 (2024)

    Σύνδεσμος πρόσβασης: https://doaj.org/article/696b45b8289b4ce68abfab2308ffb2be

  2. 2
    Academic Journal

    Συγγραφείς: N.V. Pasiechko, Yu.V. Yevstratieva

    Πηγή: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 16, Iss 8, Pp 630-635 (2020)
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine); Vol. 16 No. 8 (2020); 630-635
    Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16 № 8 (2020); 630-635
    Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16 № 8 (2020); 630-635

    Περιγραφή αρχείου: application/pdf

  3. 3
  4. 4
  5. 5
  6. 6
    Academic Journal

    Πηγή: Rheumatology Science and Practice; Vol 61, No 5 (2023); 562-568 ; Научно-практическая ревматология; Vol 61, No 5 (2023); 562-568 ; 1995-4492 ; 1995-4484

    Περιγραφή αρχείου: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/3438/2317; Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380-390. doi:10.1038/s41584-020-0441-1; Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: Case-control study. Ann Rheum Dis. 2016; 75(1): 210-217. doi:10.1136/annrheumdis-2014-206410; Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: An update on prevalence and treatment options. BMC Med. 2017;15(1):123. doi:10.1186/s12916-017-0890-9; Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900. doi:10.1161/CIRCULATIONAHA.107.703389; Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-2696. doi:10.1002/art.22014; De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK. Independent impact of gout on the risk of acute myocardial infarction among elderly women: A population-based study. Ann Rheum Dis. 2010;69(6):1162-1164. doi:10.1136/ard.2009.122770; Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI, et al. Uric acid and hypertension: An update with recommendations. Am J Hypertens. 2020;33(7):583-594. doi:10.1093/ajh/hpaa044; Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991-F997. doi:10.1152/ajprenal.00283.2001; Park JJ, Roudier MP, Soman D, Mokadam NA, Simkin PA. Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study. BMJ Open. 2014;4(7):e005308. doi:10.1136/bmjopen-2014-005308; Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707; Российское кардиологическое общество. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi:10.15829/1560-4071-2020-4076; 2021 рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике. Российский кардиологический журнал. 2022;27(7):5155. doi:10.15829/1560-4071-2022-5155; Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339; Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. doi:10.1136/annrheumdis-2021-221733; Liu SC, Xia L, Zhang J, Lu XH, Hu DK, Zhang HT, et al. Gout and risk of myocardial infarction: A systematic review and metaanalysis of cohort studies. PLoS One. 2015;10(7):e0134088. doi:10.1371/journal.pone.0134088; Huang KH, Tai CJ, Tsai YF, Kuan YH, Lee CY. Correlation between gout and coronary heart disease in Taiwan: A nationwide population-based cohort study. Acta Cardiol Sin. 2019;35(6):634-640. doi:10.6515/ACS.201911_35(6).20190403B; Liang L, Hou X, Bainey KR, Zhang Y, Tymchak W, Qi Z, et al. The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis. Clin Cardiol. 2019;42(11):1079-1086. doi:10.1002/clc.23266; Wijnands JM, Boonen A, Dagnelie PC, van Greevenbroek MM, van der Kallen CJ, Ferreira I, et al. The cross-sectional association between uric acid and atherosclerosis and the role of low-grade inflammation: the CODAM study. Rheumatology (Oxford). 2014;53(11):2053-2062. doi:10.1093/rheumatology/keu239; Essex MN, Hopps M, Bienen EJ, Udall M, Mardekian J, Makinson GT. Evaluation of the relationship between serum uric acid levels and cardiovascular events in patients with gout: A retrospective analysis using electronic medical record data. J Clin Rheumatol. 2017;23(3):160-166. doi:10.1097/RHU.0000000000000496; Wu J, Lei G, Wang X, Tang Y, Cheng H, Jian G, et al. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities. Oncotarget. 2017;8(46):80688-80699. doi:10.18632/oncotarget.21079; Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther. 2010;12(2):206. doi:10.1186/ar2952; Schjerning A-M, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020;17(9):574-584. doi:10.1038/s41569-020-0366-z; Yang Y, Xian W, Wu D, Huo Z, Hong S, Li Y, et al. The role of obesity, type 2 diabetes, and metabolic factors in gout: A Mendelian randomization study. Front Endocrinol (Lausanne). 2022;13:917056. doi:10.3389/fendo.2022.917056; Барскова ВГ, Ильиных ЕВ, Елисеев МС, Зилов АВ, Насонов ЕЛ. Кардиоваскулярный риск у больных подагрой. Ожирение и метаболизм. 2006;3(8):40-44.; Маркелова ЕИ, Елисеев МС, Попкова ТВ, Ильиных ЕВ, Глухова СИ, Барскова ВГ. Распространенность и факторы риска развития артериальной гипертонии у пациентов с подагрой. Научно-практическая ревматология. 2020;58(6): 701-707. doi:10.47360/1995-4484-2020-701-707; Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: Meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90. doi:10.1186/s13075-015-0610-9; Yu KH, Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, et al. Risk of end-stage renal disease associated with gout: A nationwide population study. Arthritis Res Ther. 2012;14(2):R83. doi:10.1186/ar3806

  7. 7
    Academic Journal

    Συνεισφορές: The work was conducted within the framework of fundamental scientific research No. 122020300043-1 “Molecular cellular mechanisms of development of cardiovascular diseases of ischemic and non-ischemic genesis. Fundamental aspects of the implementation of organoprotective effects of therapeutic interventions”.

    Πηγή: Medical Immunology (Russia); Том 25, № 4 (2023); 971-976 ; Медицинская иммунология; Том 25, № 4 (2023); 971-976 ; 2313-741X ; 1563-0625

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.mimmun.ru/mimmun/article/view/2768/1809; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2768/11508; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2768/11509; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2768/11510; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2768/11511; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2768/11512; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2768/11513; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2768/11514; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2768/11516; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2768/12119; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2768/12135; Castillo L., Rohatgi A., Ayers C.R., Owens A.W., Das S.R., Khera A., McGuire D.K., de Lemos J.A. Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the dallas heart study. J. Interferon Cytokine Res., 2010, Vol. 30, no. 5, pp. 339-347.; Emanuele E., Falcone C., D’Angelo A., Minoretti P., Buzzi M.P., Bertona M., Geroldi D. Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis, 2006, Vol. 186, no. 1, pp. 140-145.; Grievink H.W., Smit V., Huisman B.W., Gal P., Yavuz Y., Klerks C., Binder C.J., Bot I., Kuiper J., Foks A.C., Moerland M. Cardiovascular risk factors: The effects of ageing and smoking on the immune system, an observational clinical study. Front. Immunol., 2022, Vol. 13, 968815. doi:10.3389/fimmu.2022.968815.; Haley K.J., Lilly C.M., Yang J.H., Feng Y., Kennedy S.P., Turi T.G., Thompson J.F., Sukhova G.H., Libby P., Lee R.T. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation, 2000, Vol. 102, no. 18, pp. 2185-2189.; Hughes C.E., Nibbs R.J.B. A guide to chemokines and their receptors. FEBS J., 2018, Vol. 285, no. 16, pp. 2944-2971.; Kaveshnikov V.S., Trubacheva I.A., Serebryakova V.N. Analysis of factors associated with arterial stiffness in the general working-age population. Russian Journal of Cardiology, 2022, Vol. 27, no. 5, pp. 64-70. (In Russ.); Kodali R.B., Kim W.J., Galaria I.I., Miller C., Schecter A.D., Lira S.A., Taubman M.B. CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler. Thromb. Vasc. Biol., 2004, Vol. 24, no. 7, pp. 1211-1216.; Mosedale D.E., Smith D.J., Aitken S., Schofield P.M., Clarke S.C., McNab D., Goddard H., Gale C.R., Martyn C.N., Bethell H.W., Barnard C., Hayns S., Nugent C., Panicker A., Grainger D.J. Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction. Atherosclerosis, 2005, Vol. 183, no. 2, pp. 268-274.; Raghuraman G., Hsiung J., Zuniga M.C., Baughman B.D., Hitchner E., Guzman R.J., Zhou W. Eotaxin augments calcification in vascular smooth muscle cells. J. Cell. Biochem., 2017, Vol. 118, no. 3, pp. 647-654.; Rastogi T., Girerd N., Lamiral Z., Bresso E., Bozec E., Boivin J.M., Rossignol P., Zannad F., Ferreira J.P. Impact of smoking on cardiovascular risk and premature ageing: Findings from the STANISLAS cohort. Atherosclerosis, 2022, Vol. 346, pp. 1-9.; Rotar O.P., Tolkunova K.M. EVA and SUPERNOVA concepts of vascular aging: ongoing research on damaging and protective risk factors. Arterial Hypertension, 2020, Vol. 26, no. 2, pp. 133-145. (In Russ.); Saiki A., Ohira M., Yamaguchi T., Nagayama D., Shimizu N., Shirai K., Tatsuno I. New horizons of arterial stiffness developed using Cardio-Ankle Vascular Index (CAVI). J. Atheroscler. Thromb., 2020, Vol. 27, no. 8, pp. 732-748.; Sumin A.N., Shcheglova A.V. Assessment of arterial stiffness using the cardio-ankle vascular index – what we know and what we strive for. Rational Pharmacotherapy in Cardiology, 2021, Vol. 17, no. 4, pp. 619-627. (In Russ.); Vasudevan A.R., Wu H., Xydakis A.M., Jones P.H., Smith E.O., Sweeney J.F., Corry D.B., Ballantyne C.M. Eotaxin and obesity. J. Clin. Endocrinol. Metab., 2006, Vol. 91, no. 1, pp. 256-261.; https://www.mimmun.ru/mimmun/article/view/2768

  8. 8
  9. 9
  10. 10
    Academic Journal

    Πηγή: Medicine in Kuzbass; Том 21, № 3 (2022): сентябрь; 69-74 ; Медицина в Кузбассе; Том 21, № 3 (2022): сентябрь; 69-74 ; 2588-0411 ; 1819-0901

    Περιγραφή αρχείου: text/html; application/pdf

  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
    Academic Journal

    Πηγή: Rational Pharmacotherapy in Cardiology; Vol 15, No 4 (2019); 478-483 ; Рациональная Фармакотерапия в Кардиологии; Vol 15, No 4 (2019); 478-483 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2019-15-4

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1998/1844; Global Adult Tobacco Survey, Russian Federation, 2016, Executive summary [cited by Aug 01, 2019]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0012/347979/GATS-2016-rus-ES-FINAL-170906.pdf.; Teo K.K., Ounpuu S., Hawken S., et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet. 2006;368(9536):64758. DOI:10.1016/S0140-6736(06)69249-0.; WHO. Global health risks: Mortality and burden of disease attributable to selected major risks. Non serial Publication. Geneva: World Health Organization; 2009 [cited by Aug 01, 2019]. Available from: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=15&codcch=77.; Jain R.M., Ducatman A. Associations between smoking and lipid/lipoprotein concentrations among US adults aged > 20 years. J Circ Biomark. 2018;7:1849454418779310. DOI:10.1177/1849454418779310.; Ambrose J.A., Rajat S., Barua R.S. The Pathophysiology of Cigarette Smoking and Сardiovascular Disease An Update. The Pathophysiology of Cigarette. J Am Coll Cardiol. 2004;43:1731-7. DOI:10. 1016/j.jacc.2003.12.047.; Климов А.Н., Никульчева Н.Г. Обмен липидов и липопротеидов и его нарушения. СПб.: Питер Ком; 1999.; National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.; Komiya H., Mori Y., Yokose T., et al. Smoking as a risk factor for visceral fat accumulation in Japanese men. Tohoku J Exp Med. 2006;208(2):123-32. DOI:10.1620/tjem.208.123.; Meenakshisundaram R., Rajendiran C., Ponniah Thirumalaikolundusubramanian P. Lipid and lipoprotein profiles among middle aged male smokers: a study from southern India. Tobacco Induced Diseases. 2010;8:11. DOI:10.1186/1617-9625-8-11.; Campbell S.C., Moffatt R.J., Stamford B.A. Smoking and smoking cessation ‒ The relationship between cardiovascular disease and lipoprotein metabolism: A review. Atherosclerosis. 2008;201:22535. DOI:10.1016/j.atherosclerosis.2008.04.046.; How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010.; Koda M., Kitamura I., Okura T., et al. The Associations Between Smoking Habits and Serum Triglyceride or Hemoglobin A1c Levels Differ According to Visceral Fat Accumulation. Epidemiol. 2016;26(4):208-15. DOI:10.2188/jea.JE20150086.; Gossett L.K., Johnson H.M., Piper M.E., et al. Smoking Intensity and Lipoprotein Abnormalities in Active Smokers. J Clin. Lipidol. 2009;3(6):372-8. DOI:10.1016/j.jacl.2009.10.008.; https://www.rpcardio.com/jour/article/view/1998

  19. 19
  20. 20